Funding

STRM.BIO

United States · Biotech

Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy

Visit strm.bioFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Seed2$8MBlue Bay Capital Fund — Role not disclosedBoehringer Ingelheim Ventures — Role not disclosedDelos Capital — Role not disclosedRecordati — Role not disclosed

Investors

Blue Bay Capital FundSeed2Boehringer Ingelheim VenturesSeed2Delos CapitalSeed2RecordatiSeed2

Coverage

Jan 7, 2026STRM.BIO · Seed2

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesstrm.bio ↗